

EQA round: KM2/24 - Cardiac Markers

Deadline: 23.8.2024

Setup: Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1														
(218) CK-MB mass	[µg/L]				10							8	7	88
Sample A1		8,06	0,82	10	10							8	8	100
(60) Roche		7,83	0,24	3	5	0	CVPG	7,7	0,32	27%	5,62	9,78	5	
Other					5	0							3	
								1x 1, 2x 12, 1x 61, 1x 179						
Sample B1		58,5	7,1	12	10							8	7	88
(60) Roche		56,1	2,4	4,3	5	0	CVPG	54,8	2,2	27%	40	69,6	5	
Other					5	0							3	
								1x 1, 2x 12, 1x 61, 1x 179						
(444) Homocysteine	[µmol/L]				24							19	14	74
Sample A1		3,23	0,97	30	24							19	15	79
(109) Axis-Shield		2,65	0,38	14	9	0	CVPG	2,86	0,5	42%	1,65	4,07	9	
Other					15	0							10	
								4x 1, 1x 58, 4x 60, 2x 75, 2x 179, 2x 999						
Sample B1		3,23	1	32	24							19	15	79
(109) Axis-Shield		2,91	0,87	30	9	0	CVPG	2,93	0,61	42%	1,69	4,17	9	
Other					15	0							10	
								4x 1, 1x 58, 4x 60, 2x 75, 2x 179, 2x 999						
(441) Myoglobin	[µg/L]				25							23	23	100
Sample A1		93,2	9,8	10	25							23	23	100
(60) Roche		97,7	4,5	4,6	16	0	CVPG	97,1	1	22%	75,7	119	16	
Other					9	0							7	
								3x 843, 1x 1, 2x 12, 2x 178, 1x 179						
Sample B1		309	31	9,9	25							23	23	100
(60) Roche		318	18	5,7	16	0	CVPG	317	3,8	22%	247	387	16	
Other					9	0							7	
								3x 843, 1x 1, 2x 12, 2x 178, 1x 179						
(447) NT-proBNP	[ng/L]				53							51	47	92
Sample A1		205	31	15	53							51	47	92
(1) Abbott		249	28	11	8	0	CVPG	253	4,6	27%	184	322	8	
(60) Roche		192	11	5,8	38	0	CVPG	189	2,4	27%	137	241	38	
Other					7	0							5	
								1x 12, 1x 15, 2x 54, 2x 61, 1x 179						
Sample B1		824	120	14	53							51	48	94
(1) Abbott		969	110	11	8	0	CVPG	1010	13	27%	737	1290	8	
(60) Roche		777	40	5,1	38	0	CVPG	764	9,4	27%	557	971	38	
Other					7	0							5	
								1x 12, 1x 15, 2x 54, 2x 61, 1x 179						
(442) Troponin I	[ng/L]				17							17	15	88
Sample A1		4,39	1,9	43	17							17	16	94
(1) Abbott		5,5	0,74	13	5	0	CVPG	5,77	0,19	±2,7	3,07	8,47	5	
(12) Beckman Coulter		2,9	1	36	9	1	CVPG	3,21	0,28	±2,7	0,51	5,91	9	
Other					3	0							3	
								1x 54, 2x 179						
Sample B1		44,9	30	66	17							17	15	88
(1) Abbott		68,4	4,7	6,8	5	0	CVPG	69,5	1,3	27%	50,7	88,3	5	
(12) Beckman Coulter		20,7	5,4	26	9	1	CVPG	22,7	1,5	27%	16,5	28,9	9	
Other					3	0							3	
								1x 54, 2x 179						
(443) Troponin T	[ng/L]				40							39	39	100
Sample A1		16,9	1,5	8,7	40							39	39	100
(2) Immunochemical methods (hs); (60) Roche		17	1,4	8,4	39	0	CVPG	16,9	0,25	22%	13,1	20,7	39	
Other					1	0							0	
								1x 1/61						
Sample B1		79,6	5,3	6,7	40							39	39	100
(2) Immunochemical methods (hs); (60) Roche		79,8	5,2	6,5	39	0	CVPG	81,3	1,1	22%	63,4	99,2	39	
Other					1	0							0	
								1x 1/61						
Set 2														
(449) BNP	[ng/L]				3							1	1	100
Sample A2					3	0						1	1	100
Other					3	0						1		
								1x 1, 1x 12, 1x 179						

EQA round: KM2/24 - Cardiac Markers

Deadline: 23.8.2024

Setup: Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Sample B2												1	1	100
Other					3	0						1		
							1x 1, 1x 12, 1x 179							